Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data of a drug to treat myeloma and raised $125 million to fund upcoming trials.

International Business Times UK

Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying'

Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative “a good start,” while still acknowledging its limitations.

Benzinga

TrumpRx.Gov vs. Mark Cuban’s Cost Plus Drugs: Which Saves Retirees More?

Billionaire celebrity Mark Cuban disrupted the prescription drug industry when he launched the digital pharmaceutical marketplace CostPlus Drugs in 2022. President Donald Trump recently announced a...

GOBankingRates

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Birth Control Scandal: 1,000 Women Sue Over Brain Tumour Risk After Using Popular Contraceptive

Pfizer faces lawsuits from 1,000 women alleging Depo-Provera birth control caused brain tumours, amid new research showing higher meningioma risk.

International Business Times UK

Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032

Novo Nordisk A/S (NASDAQ:NVO) is back in the headlines, and not just for its blockbuster weight-loss drug, Ozempic. President Donald Trump recently suggested a dramatic price cut for the drug, sparking some short-term market jitters. But underneath the noise, the stock is cheap at a 14 P/E, and its core…

Benzinga

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare…

Benzinga

5 Things Retirees Need To Know About the New Trump Drug Program

Will TrumpRx help cut prescription costs for uninsured retirees? Learn how this new drug program could impact retirees' prescription budgets come 2026.

GOBankingRates

Read news from The Economist, FT, and more,
with one subscription

Pfizer’s Q3 2025 Earnings: What to Expect

Pfizer is expected to report its third-quarter results next month, and analysts are projecting a double-digit decline in its earnings.

Barchart

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug

Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.

Benzinga

Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices

AstraZeneca joins Pfizer in cutting US drug prices under Trump's new deal to offer lower costs for Medicaid patients.

International Business Times

AstraZeneca Joins Trump's Push to Make Medicines Cheaper — But Why Are Critics Skeptical?

US President Donald Trump announced a deal with UK pharmaceutical AstraZeneca to lower certain drugs for government's Medicaid health plan.

International Business Times UK

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Guardian - US

AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration

The Independent UK

Trump announces AstraZeneca will offer discount drugs on ‘TrumpRx’ website

TrumpRx.gov, a website where Americans can buy pharmaceutical drugs under President Donald Trump’s new drug pricing plan, is set to begin operation in 2026

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

5 Healthcare Plays Powering the Sector’s Big Comeback

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

The Guardian - UK

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

MarketBeat

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

MarketBeat

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

MarketBeat

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Benzinga

Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets

Wall Street soared to fresh record highs at the end of the week, brushing aside the 21st U.S. government shutdown in history and a missing jobs report, as investors doubled down on bets for interest rate cuts and cheered strong gains in pharmaceutical and AI-driven tech stocks.

Benzinga

These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap

Health care stocks are on track for their best week in years, yet even after the rally, several pharma giants remain absurdly cheap by market standards.

Reason

TrumpRx Is Obamacare in Trump's Handwriting

Pfizer wins big in Trump’s new drug discount gimmick.

Fortune

Mark Cuban says Trump’s new drug platform could succeed if it forces pharma managers to change: ‘If that happens, Trump gets all the credit’

Cuban’s Cost Plus Drugs, which he founded in 2022, similarly provides direct-to-consumer discounted pharmaceuticals.

MarketBeat

Top 3 Dividend Achievers for October: High Yields, Growth Ahead

High-yield Dividend Achievers, such as United Parcel Service, Verizon, and Pfizer, offer attractive entry points in October for income investors.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.